Genentech Logo

Scientist Profile

Lesley Murray

Principal Project Manager, Drug Metabolism & Pharmacokinetics
Back to Scientist Profiles
 
"A turning point for me was when...I was myself diagnosed with pre-breast cancer (DCIS). Receiving radiation every day for six weeks and watching other patients go through this ordeal reinforced my hope that there must be a better way to conquer this terrible disease."

I joined Genentech in November 2003 as Associate Director of Small Molecule Translational Oncology. In that role, I built a new Pharmacology group to provide PK/PD and efficacy data in Oncology mouse models to support Genentech's small molecule program.

Within four years, I hired six scientists and many skilled RAs and dosing technicians to form an effective group of 40 people. In 2006, I contributed the Pharmacology sections to the IND filings for GDC-0449 Hedgehog inhibitor, which is now in Phase II, and for GDC-0152 IAP antagonist, now in Phase I. I enjoyed the experience of being a member of the Pharmacology subteams (PST) for these two molecules, as well as contributing to the Core team for Mek inhibitor XL518.

See More

 
 
My Focus

In May 2008, I transitioned into my new role as Principal Project Manager within the DMPK group, leading an Oncology small molecule back-up research project in collaboration with Array, Boulder, Colorado.

Also I support the lead kinase inhibitor for this target in Early Development, sitting on both the Core and PST teams. I am also dedicated to working with other project team leaders to ensure optimal use of PK/PD and early safety studies during the research phase. In addition, I am helping to link research and clinical PD efforts that are both so important to pick the right drug candidates and ensure that they effectively inhibit their targets in patients.

See More

 
Publications & Recognition
  • Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
  • Cancer Res 2006 Jan 15; 66(2): 999-1006
  • Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S.
  • View Abstract on PubMed
  • SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
  • Clin Exp Metastasis 2003; 20(8): 757-66
  • Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK
  • View Abstract on PubMed
  • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
  • Clin Cancer Res 2003 Jan; 9(1): 327-37
  • Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM
  • View Abstract on PubMed
 
View All Publications & Recognition
 
  • National Institute of Medical Research
  • Postdoctoral Fellow
  • Imperial Cancer Research Fund and University College
  • Ph.D
  • University of Cambridge
  • B.A.
Publications & Recognition
  • Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
  • Cancer Res 2006 Jan 15; 66(2): 999-1006
  • Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S.
  • View Abstract on PubMed
  • SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
  • Clin Exp Metastasis 2003; 20(8): 757-66
  • Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK
  • View Abstract on PubMed
  • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
  • Clin Cancer Res 2003 Jan; 9(1): 327-37
  • Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM
  • View Abstract on PubMed
  • Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture
  • Hum Gene Ther 1999 Jul 20; 10(11): 1743-52
  • Murray L, Luens K, Tushinski R, Jin L, Burton M, Chen J, Forestell S, Hill B
  • View Abstract on PubMed
  • Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division
  • Exp Hematol 1999 Jun; 27(6): 1019-28
  • Murray LJ, Young JC, Osborne LJ, Luens KM, Scollay R, Hill BL
  • View Abstract on PubMed
  • Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer
  • Ann Intern Med 1997 May 1; 126(9): 673-81
  • Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE
  • View Abstract on PubMed
  • Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis, and expansion of CD34+ progenitor cells from single CD34+Thy-1+Lin- primitive progenitor cells
  • Blood 1996 Sep 1;88(5): 1619-31
  • Young JC, Bruno E, Luens KM, Wu S, Backer M, Murray LJ
  • View Abstract on PubMed
  • Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood
  • Blood 1995 Jan 15; 85(2): 368-78
  • Murray L, Chen B, Galy A, Chen S, Tushinski R, Uchida N, Negrin R, Tricot G, Jagannath S, Vesole D, Barlogie B, Hoffman R, Tsukamoto A
  • View Abstract on PubMed
  • Isolation of both normal and leukemic cells within the hematopoietic stem cell compartment of chronic myelogenous leukemia mobilized peripheral blood. In "Autologous Stem Cell Transplantation. Biological and Clinical Results in Malignancies"
  • Ed Angelo M. Carella, Harwood Academic. 1997. p. 27
  • Tsukamoto A S, Van Den Berg D, Reading C, Tong J, Murray L, Carella A, Frassoni F, Snyder D, Herzig G, Gorin C, LaPorte J, Negrin R, Blume K, Cunningham I, Claxton D, Deisseroth A, Hoffman R
  • Low-grade lymphomas. In "Malignant lymphomas" (Current Problems in Tumor Pathology). Eds. J A Habeshaw and I Lauder
  • Churchill Livingstone, Edinburgh, London, Melbourne and New York. 1988, p. 127-168
  • Swerdlow S H and Murray, L J.
See More

Ellen Filvaroff, Senior Scientist and Alex Avardo, Receipent of Free Medicine From the Genentech® Access to Care Foundation, on the cover of Genentech's 2006 Annual Report.